Lenvatinib treatment for advanced bone or soft tissue sarcoma
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 10–70 (any sex).
- Your performance status is 0–1 (or amputation may allow a slightly higher score), and your expected survival is at least 3 months.
- Your sarcoma is advanced or has spread (distant metastases) and your doctor believes surgery isn’t suitable.
- You have measurable tumor spots on scans that can be followed (meet RECIST 1.1).
- Any prior treatment side effects are mostly gone by the first dose day (grade 0–1), except hair loss if your doctor feels it’s safe.
- You meet key safety lab and heart/thyroid requirements, and you’re not dealing with certain serious infections or uncontrolled medical problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, radiation, and two newer drugs (anlotinib and bempegaldesleukin) for people with advanced soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
This trial tests a combination of paclitaxel polymer micelles with other drugs for people with advanced bone or soft tissue sarcoma that has worsened after first-line chemotherapy. The goal is to see if this new formulation can help shrink tumors or slow their growth.
This trial tests whether adding lenvatinib (a targeted cancer drug) to everolimus (an immunosuppressant that fights cancer) works better than everolimus alone for advanced bone cancers like osteosarcoma, Ewing sarcoma, or chondrosarcoma that have progressed despite prior chemotherapy.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Hear when a new Effectiveness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.